Chinese Biotech Firm Magpie Pharmaceuticals Raises Nearly $15M In Series B Round

Guangzhou-based biotechnology company Magpie Pharmaceuticals announced on Monday that it has raised a nearly RMB100 million (US$14.8 million) series B financing round from Chinese venture capital firm Sangel Capital. Magpie Pharmaceuticals was founded in 2010 to specialize in the research and development of first-in-class drugs. The company focuses on the structural modification and transformation of […]

Chinese Biotech Firm Magpie Pharmaceuticals Raises Nearly $15M In Series B Round comes originally from China Money Network. All Rights Reserved.

Read the original article: China Money Network